Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases.
Zhang K, Lian Y, Guan X, Hu Q, Lei L, Tao L, He D, Lin J, Hou Z, Ren L, Liu X, Ren Q, Pan L, Fei X, Xiong M, Wen S, Cao J.
Zhang K, et al. Among authors: he d.
Ann Hematol. 2020 Nov;99(11):2539-2546. doi: 10.1007/s00277-020-04268-z. Epub 2020 Sep 17.
Ann Hematol. 2020.
PMID: 32939674
Clinical Trial.